Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Zhu Ji, Doctor of Medicine
CONTACT
Sun yan, Doctor of Medicine
CONTACT
Lead
TYK Medicines, Inc
This is an open-label, multi-center, dose-escalation and expansion phase Ib/II study to evaluate dose limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) in subjects with metastatic castration-resistant prostate cancer (mCRPC). To evaluate the efficacy of TY-302 combined with Abiraterone tablets in subjects with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted